Home›Psychiatry› MBSR matches escitalopram for GAD anxiety, with high-certainty evidence
MBSR matches escitalopram for GAD anxiety, with high-certainty evidenceMindfulness Training Shows Similar Results to Medication for Anxiety
medRxivPublished October 24, 2026Study authors: Vieira Neves, V.; Larbi, N. A. O. O.; Acabchuk, R. L.; Haygood, L. N.; Rajasankar, V.; Goldberg, S. …DOI ↗Editorial oversight: Dr. Ji-eun Park, MD · Brain, Mind & Pain
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider MBSR as a nonpharmacologic option for GAD, though replication is needed.
This meta-analysis synthesized evidence on Mindfulness-Based Stress Reduction (MBSR) for adults with generalized anxiety disorder (GAD), drawing on a total sample of 1,012 participants. Comparators included waitlist, general active comparators, and escitalopram. The primary outcome was anxiety symptoms, with adverse events as a secondary outcome.
MBSR was associated with significant reductions in anxiety symptoms versus waitlist (Hedges' g=-0.88, 95% CI -1.57 to -0.19) and versus general active comparators (Hedges' g=-0.85, 95% CI -1.15 to -0.54). Against escitalopram, MBSR showed no significant difference in anxiety symptoms (Hedges' g=0.09, 95% CI -0.11 to 0.29). GRADE certainty was high for the escitalopram comparison and very low for waitlist.
Adverse events were reported as 15% in an in-person trial versus 79% in the other trial, and MBSR was described as well-tolerated. Serious adverse events and discontinuations were not reported. The authors note that independent replication is needed, and funding or conflicts of interest were not reported.
For practice, MBSR may be a viable nonpharmacologic option for adults with GAD, particularly those who prefer non-drug management or cannot tolerate medication. The high-certainty equivalence to escitalopram is notable, but the need for replication and the very low certainty for waitlist comparisons warrant cautious interpretation.
How this fits prior evidence
This meta-analysis extends prior coverage of mindfulness-based approaches in anxiety and mood disorders. Previous coverage reported that MBCT plus escitalopram improved cognitive function and depression severity in older adults with treatment-resistant depression, supporting a role for mindfulness-based interventions alongside pharmacotherapy. The current findings suggest MBSR may be comparable to escitalopram for GAD anxiety symptoms, broadening the potential use of mindfulness-based approaches beyond depression. Prior coverage also highlighted caution with SSRI combinations in Parkinson's patients, a safety consideration distinct from the present comparison of MBSR versus escitalopram monotherapy.
Researchers looked at how Mindfulness-Based Stress Reduction (MBSR) helps adults with generalized anxiety disorder. They compared this mindfulness program against a waitlist, other active treatments, and the medication escitalopram. The study included over 1,000 participants to see how well each method reduced anxiety symptoms.
The results showed that MBSR significantly reduced anxiety symptoms compared to both a waitlist and other active treatments. When compared directly to the medication escitalopram, the study found no significant difference in how well the two options reduced anxiety. This suggests that mindfulness programs can be an effective way to manage symptoms.
MBSR was found to be well-tolerated by participants. While the evidence for comparing MBSR to medication is considered high quality, the evidence for comparing it to a waitlist is low. Because this was a meta-analysis, more independent studies are needed to confirm these findings. Patients who prefer non-drug options or cannot tolerate medication may find mindfulness a viable choice.
What this means for you:
Mindfulness-based stress reduction may be as effective as escitalopram for managing generalized anxiety symptoms.
Common questions
Is mindfulness as effective as medication for anxiety?
The study found no significant difference in anxiety symptom reduction between Mindfulness-Based Stress Reduction (MBSR) and the medication escitalopram. This suggests that for adults with generalized anxiety disorder, mindfulness can be a comparable option to certain medications.
What are the side effects of mindfulness-based stress reduction?
The study reported that Mindfulness-Based Stress Reduction was well-tolerated by participants. While some adverse events were noted in specific trials, the program is considered a non-pharmacologic treatment option for those who prefer to avoid medication.
Who can benefit from mindfulness for anxiety?
Mindfulness-based stress reduction can be a viable option for adults with generalized anxiety disorder. It may be especially helpful for patients who prefer non-pharmacological management or for those who cannot tolerate the side effects of medication.
Objective: To evaluate the efficacy and safety of Mindfulness-Based Stress Reduction (MBSR) for anxiety symptoms in adults with generalized anxiety disorder (GAD). Design: Systematic review and meta-analysis. Data Sources: CINAHL, Embase, MEDLINE, PsycINFO, Scopus, SocINDEX, ERIC (EBSCO), and ProQuest Dissertations & Theses Global were searched from inception to October 2025; identified trial protocols were hand-searched for subsequent reports through February 2026. Eligibility criteria for selecting studies: Randomized, non-randomized, and single-arm trials evaluating the effects of MBSR on anxiety in adults with GAD. Data extraction and synthesis: Two authors independently screened records, extracted data, and assessed risk of bias. The primary outcome was anxiety symptoms; the secondary outcome was adverse events. Random-effects meta-analyses were conducted, and certainty of evidence was assessed. Results: Of 19 included reports (16 independent samples), 8 randomized controlled trials (n=1,012) were included in the primary meta-analysis. MBSR significantly reduced anxiety symptoms vs. waitlist (Hedges' g=-0.88; 95% CI -1.57 to -0.19) and general active comparators (g=-0.85; 95% CI -1.15 to -0.54), and showed no significant difference vs. escitalopram in two linked trials (g=0.09; 95% CI -0.11 to 0.29), with fewer adverse events in the in-person trial, the only one reporting them (15% vs. 79%; number needed to treat to avoid harm=2). GRADE certainty of evidence was high for the escitalopram comparison and very low for waitlist. Conclusions: MBSR is a well-tolerated, nonpharmacologic treatment option for adults with GAD. Anxiety reductions were similar to escitalopram, with fewer adverse events; independent replication is needed. MBSR may be a viable option for patients who prefer non-pharmacological management or who cannot tolerate medication. Systematic review registration: PROSPERO CRD420251140213.
